Resalis Therapeutics’ transformative metabolic disease approach targets a master regulator of key pathways underlying obesity and fatty liver disease. 
 
The company is applying its unique understanding of the non-coding RNA drug modality and lipid metabolism to develop its lead program, RES-010, into a safe and convenient treatment providing disease-modifying therapeutic impact including durable weight loss and reduction of hepatic steatosis.

Building on robust preclinical evidence, Resalis will rapidly bring RES-010 into clinical trials for a range of metabolic disorders.

Biotechnology

Life Sciences

Therapeutics

Resalis Therapeutics

Resalis Therapeutics' headquarters in Turin, Italy

Alessandro Toniolo

Sakari Kauppinen

Riccardo Panella

This department provides strategic oversight and governance for the organization.

Executive Leadership

This department is responsible for overseeing medical operations and strategic development within the organization.

Medical Leadership

This department focuses on managing and facilitating research activities and initiatives in the preclinical and translational stages.

Research Operations

This department oversees the execution and coordination of operational activities to ensure efficient workflow and project delivery.

Operations Management

This department oversees project planning, coordination, and budgeting to ensure successful completion of initiatives.

Project Management

This department oversees the technological and scientific initiatives within the organization, driving innovation and strategic advancements.

Resalis Therapeutics

Org chart

Teams

Executive Leadership

Medical Leadership

Research Operations

Operations Management

Project Management

Technology and Science

Offices

Resalis Therapeutics

Org chart

Teams

Executive Leadership

Medical Leadership

Research Operations

Operations Management

Project Management

Technology and Science

Offices

Related companies